Skip to main content
Defiance International

Published study records

Study records for MOTS-c

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

237 study records.

30 evidence-verified · 158 citation-verified · 49 citation-only

Verified records by research setting

  • Human research: 73
  • In vitro: 41
  • In vivo/preclinical: 74
  • Review/meta-analysis: 0
  • Other: 0
Filter study recordsReset filters

Current study records

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

MOTS‐c protects against placental injury via Nrf2 activation in hypoxia‐induced intrauterine growth restriction mice.

International journal of molecular medicine · 2026

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor.

Molecular neurobiology · 2026

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Schematic timeline illustrating the experimental design and procedures conducted throughout the study.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Evidence verified by machine against declared source

MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.

Redox biology · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Evidence verified by machine against declared source

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.

Experimental & molecular medicine · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.

Frontiers in physiology · 2025

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

We found that untreated T2D rats had hyperglycemia, poor glucose control, and left ventricular hypertrophy relative to controls.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Characterization of the Avian Mitochondrial-Derived Peptide MOTS-c and Its Potential Role as a Metabolic Regulator.

Animals : an open access journal from MDPI · 2025

Study scale: Not reported in the declared source.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Evidence verified by machine against declared source

Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.

Clinical and experimental medicine · 2025

Study scale: We studied a cohort of 375 male patients with clinical suspicion of prostate cancer (PCa), enrolled at the Urology Clinic of the University Hospital of Sassari.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

We studied a cohort of 375 male patients with clinical suspicion of prostate cancer (PCa), enrolled at the Urology Clinic of the University Hospital of Sassari.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3.

Scientific reports · 2025

Study scale: Not reported in the declared source.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Evidence verified by machine against declared source

Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.

Theranostics · 2024

Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Mitochondria serve as critical signaling hubs within cells, which control cellular metabolism, stress response, and cell fate.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism.

Antioxidants (Basel, Switzerland) · 2024

Study scale: Not reported in the declared source.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Summary withheld

No summary text is published for this record: the text held for each field did not answer the heading it was filed under. This does not change the record’s review status.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Mitochondria-derived peptide is an effective target for treating streptozotocin induced painful diabetic neuropathy through induction of activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator 1alpha -mediated mitochondrial biogenesis.

Molecular pain · 2024

Study scale: Male C57BL/6 mice (weighing 20–22 g, 8–10 weeks-old) were purchased from the Experimental Animal Center of Xuzhou Medical University (Xuzhou, China).

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Male C57BL/6 mice (weighing 20–22 g, 8–10 weeks-old) were purchased from the Experimental Animal Center of Xuzhou Medical University (Xuzhou, China).

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

The mechanical pain threshold of mice was measured by von Frey monofilaments (Bio-VF-M, Bioseb, USA) with the up-down method.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis

Acta biochimica et biophysica Sinica · 2024

Study scale: Male C57BL/6 mice (aged 6‒10 weeks, weighing 20‒25 g) were obtained from the Experimental Animal Center of Xuzhou Medical University and were raised in cages in an air filtration system.

Abstract only: Open source record

Product or molecular entity relationships

  • MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Study scale

Male C57BL/6 mice (aged 6‒10 weeks, weighing 20‒25 g) were obtained from the Experimental Animal Center of Xuzhou Medical University and were raised in cages in an air filtration system.

Intervention or exposure

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Comparator

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Key findings

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.